Arrowhead Pharmaceuticals, Inc. (ARWR) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Pasadena, CA, United States. The current CEO is Christopher R. Anzalone.
ARWR has IPO date of 1993-12-16, 609 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $9.34B.
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Pasadena, California, that develops RNA interference (RNAi) therapeutics for the treatment of intractable diseases. The company maintains a diverse clinical pipeline targeting liver diseases, metabolic disorders, cardiovascular conditions, respiratory diseases, and rare genetic disorders, with candidates in Phase 1 through Phase 3 clinical development. Key programs include ARO-AAT for alpha-1 antitrypsin deficiency, ARO-APOC3 for hypertriglyceridemia, ARO-HIF2 for renal cell carcinoma, and JNJ-3989 for chronic hepatitis B, developed under collaboration with Janssen Pharmaceuticals. Through strategic partnerships with leading pharmaceutical companies including Janssen and Takeda, Arrowhead leverages its RNAi platform technology to address genetically validated disease targets across multiple therapeutic areas.
